U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803758) titled 'Teicoplanin Allergy Testing Using Autologous Serum (TATAS)' on Jan. 27.
Brief Summary: Allergy testing for Teicoplanin is much more unreliable than for other similar drugs. This means that we run the risk of missing serious Teicoplanin allergy, and these patients will be given another dose in future, not knowing that they are seriously allergic. Serious allergic reactions, also known as anaphylaxis, can be life threatening.
The patients which we recruit to our study will come to us through the perioperative allergy service. They will have had a reaction to a general anaesthetic, but will also have had teicoplanin as part of the anae...